Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer.

Shah, Manish A; Wainberg, Zev A; Catenacci, Daniel V T; Hochster, Howard S; Ford, James; Kunz, Pamela; Lee, Fa-Chyi; Kallender, Howard et al. · PLoS One · 2022

Where this comes from

Record sourced from PubMed, PMID 36215283.
Also identified by DOI 10.1371/journal.pone.0276211 and PMC identifier 9550092.
No licence information is recorded for this record.
Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.

Abstract

[This corrects the article DOI: 10.1371/journal.pone.0054014.].

Read the full text

View on PubMed · Publisher (DOI)